Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Udenafil SCHEMBL69463 | 0.89 | PDE5A (0.80) | PDE5A | |
| Udenafil SCHEMBL438563 | 0.89 | PDE5A (0.80) | PDE5A | |
| SCHEMBL325269 | 0.88 | PDE5A (0.74) | PDE5A | |
| SCHEMBL3236691 | 0.86 | PDE5A (0.56) | PDE5AHDAC1HDAC6HDAC2PDE3B | |
| SCHEMBL18269491 | 0.86 | PDE5A (0.62) | PDE5AHDAC1HDAC6HDAC2PDE3B | |
| SCHEMBL6285398 | 0.83 | PDE5A (0.78) | PDE5AHDAC1HDAC6HDAC2PDE3B | |
| Udenafil SCHEMBL30452348 | 0.79 | PDE5A (1.00) | PDE5AKDM4E | |
| Udenafil SCHEMBL120993 | 0.79 | PDE5A (1.00) | PDE5AKDM4E | |
| SCHEMBL23641917 | 0.78 | PDE5A (0.72) | PDE5A | |
| SCHEMBL18416780 | 0.78 | PDE5A (0.69) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581480-B1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE-V INHIBITORS | PFIZER LTD (GB) | 2006-08-23 | — | — | EP | claimed |
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | IPSEN PHARMA S.A.S. (FR) | 2024-06-06 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| US-20090227562-A1 | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor | PFIZER INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1778241-A1 | COMBINATION OF A SELECTIVE NORADRENALINE REUPTAKE INHIBITOR AND A PDEV INHIBITOR | Pfizer Limited (GB) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006016262-A1 | COMBINATION OF A SELECTIVE NORADRENALINE REUPTAKE INHIBITOR AND A PDEV INHIBITOR | PFIZER LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182519-A1 | MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN | MC4R, MC3R, MC1R | PDE5A 895/4885HDAC1 961/4885HDAC6 1375/4885 |
| US-20090227562-A1 | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor | PDE4A, PDE12, PDE4B | PDE5A 4/4885HDAC1 1080/4885HDAC6 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.